While originally developed for BCR-ABL-expressing neoplasias like chronic myelogenous leukemia (CML), these drugs have off-target effects on kinases important in mast cell disorders, including KIT, Src and Btk, [68,69]. Here, SRC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.